Equities researchers at StockNews.com began coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a "sell" rating on the stock.
BiondVax Pharmaceuticals Stock Performance
Shares of BVXV opened at $2.77 on Tuesday. The company's fifty day moving average is $6.01 and its 200-day moving average is $8.55. BiondVax Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $22.90. The firm has a market cap of $3.97 million, a price-to-earnings ratio of -0.69 and a beta of 2.65. The company has a quick ratio of 5.76, a current ratio of 5.76 and a debt-to-equity ratio of 5.92.
Get BiondVax Pharmaceuticals alerts:BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its quarterly earnings results on Wednesday, November 30th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Equities analysts expect that BiondVax Pharmaceuticals will post -0.3 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its position in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 163,423 shares of the company's stock after buying an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.About BiondVax Pharmaceuticals
(Get Rating)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
Recommended Stories
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.